MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2022-23)
- Udyam number
- UDYAM-TS-02-0002782
Market Cap
₹234 Cr
EVERESTO · BSE
Share Price
₹239.00
+1.96% today
Revenue
₹196 Cr
FY 2025-26 · +23.0% YoY
EBITDA
₹19.81 Cr
Margin 10.1%
Net Profit
₹5.55 Cr
FY 2025-26 · +537.0% YoY
P/E (TTM)
44.5x
P/B 2.9x
ROE
7.6%
ROCE 11.8%
Debt / Equity
0.67
Interest cover 49.0x
About Everest Organics Limited
Data last updated:
Everest Organics Limited is a public limited company based in Medak, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 19 February 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24230TG1993PLC015426. Its GSTIN is 36AAACE4400F1Z9 (Telangana). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 524790.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹9.97 Cr. It is led by directors including Srikakarlapudi Sirisha (Managing Director) and Hari Krishna Srikakarlapudi (Whole-Time Director).
Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Aroor Village Sadasivapet Mandal Medak, Telangana, India – 502291.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹196.16 Cr, a growth of 23% compared to the previous year. For the same year it recorded a net profit of ₹5.55 Cr (net margin 2.8%) and EBITDA of ₹19.81 Cr (EBITDA margin 10.1%). The net worth stands at ₹75.48 Cr (up 7.9% YoY). Total assets are valued at ₹128.03 Cr (up 6.6% YoY).
The company has about 387 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Everest Organics. As per MCA filings, the company has open charges of ₹73.38 Cr and satisfied charges of ₹118.08 Cr on record. Court records list 52 cases involving the company, including 36 filed by the company and 16 filed against it; 14 cases are pending. The company has 7 deals on record (3 market trades, 3 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹38.39 Cr; the latest was in June 2025. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is S.V. Labs Private Limited with revenue of ₹162.99 Cr. The company has 18 MSME Form 1 returns on record between 2019 and 2024, listing 3,449 overdue payments to 111 micro and small suppliers.
Everest Organics Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0002782). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website everestorganicsltd.com.
Company details
CIN L24230TG1993PLC015426
Registration Number 015426
Incorporation Date 19 February 1993
ROC Hyderabad
Listing Status Listed - Listed on BSE (524790)
Company Status Active
Date of Last AGM 27 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0002782
CIN history
Everest Organics has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230TG1993PLC015426, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1993PLC015426 | Current |
| L24230AP1993PLC015426 | Previous |
| U24230AP1993PLC015426 | Previous |
Key People
Srikakarlapudi Sirisha Managing Director Hari Krishna Srikakarlapudi Whole-Time Director Venkata Satya Subbarao Pachigolla Whole-Time Director Recognitions & Rankings of Everest Organics
Contact details
Everest Organics Limited's registered office is in Medak, Telangana. Its website is everestorganicsltd.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressAroor Village Sadasivapet Mandal Medak, Telangana, India – 502291
- IndustryPharma, API Manufacturers
To see the full contact details of Everest Organics Limited, buy the company report.
Comprehensive company report
Everest Organics Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Everest Organics operates one associated brand: Everest Organics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs and pharmaceutical intermediates are manufactured by Everest Organics. | everestorganicsltd.com |
Business activity
The main business activity of Everest Organics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Everest Organics Limited, buy the company report.
Financials of Everest Organics Limited
FY 2025-26 filings availableEverest Organics Limited reported revenue of ₹196.16 Cr (up 23% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹196 Cr
+23.0% YoY
EBITDA
₹19.81 Cr
+173.2% YoY
Profit After Tax
₹5.55 Cr
+537.0% YoY
Net Worth
₹75.48 Cr
+7.9% YoY
Total Assets
₹128 Cr
+6.6% YoY
Total Debt
₹49.93 Cr
+4.3% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 196 | 159 | 197 | 183 | 200 | 182 | 167 |
| Revenue growth | +23.0% | -19.1% | +7.8% | -8.5% | +10.2% | +8.6% | - |
| EBITDA | 19.81 | 7.25 | 10.99 | 0.93 | 6.43 | 22.84 | 19.16 |
| EBITDA margin | +10.1% | +4.6% | +5.6% | +0.5% | +3.2% | +12.6% | +11.5% |
| Profit before tax | 8.05 | (3.22) | 0.61 | 0.09 | 1.74 | 17.27 | 14.08 |
| Net profit | 5.55 | (1.27) | 0.14 | (0.09) | 1.14 | 13.71 | 10.88 |
| Net profit margin | +2.8% | -0.8% | +0.1% | -0.1% | +0.6% | +7.6% | +6.5% |
| EPS (₹) | 5.71 | (1.33) | 0.17 | (0.23) | 1.43 | 17.14 | 13.62 |
| Balance sheet | |||||||
| Total assets | 128 | 120 | 105 | 99.52 | 89.34 | 71.52 | 56.57 |
| Net worth | 75.48 | 69.95 | 45.84 | 46.21 | 46.80 | 46.58 | 34.20 |
| Total debt | 49.93 | 47.87 | 57.79 | 51.05 | 38.78 | 22.90 | 17.94 |
| Cash & bank | 0.65 | 6.64 | 0.83 | 0.83 | 0.65 | 1.66 | 2.00 |
| Net working capital | 57.90 | 46.64 | 33.04 | 34.30 | 33.12 | 28.97 | 18.45 |
| Cash flow | |||||||
| Cash from operations | 4.17 | (5.38) | 16.42 | 18.42 | 13.74 | 13.53 | 9.71 |
| Cash from investing | (1.72) | (5.17) | (13.32) | (15.59) | (16.82) | (11.82) | (6.31) |
| Cash from financing | (8.45) | 16.36 | (3.10) | (2.65) | 2.07 | (2.05) | (3.36) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.43 | 48.75 | 42.59 | 51.00 | 53.81 | 40.93 | 42.05 | 44.05 |
| Revenue growth (YoY) | -10.0% | +19.1% | +1.3% | +15.8% | +65.8% | - | - | - |
| Other income | 0.42 | 0.16 | 0.25 | 0.29 | 0.55 | 0.22 | 0.00 | 0.14 |
| Total expenses | 44.10 | 42.05 | 39.05 | 45.87 | 49.38 | 37.50 | 38.03 | 40.62 |
| EBITDA | 4.33 | 6.70 | 3.54 | 5.13 | 4.43 | 3.43 | 4.02 | 3.43 |
| EBITDA margin | +8.9% | +13.7% | +8.3% | +10.1% | +8.2% | +8.4% | +9.6% | +7.8% |
| Depreciation | 1.59 | 1.93 | 1.52 | 1.52 | 1.52 | 1.56 | 1.47 | 1.47 |
| Interest | 1.63 | 2.76 | 1.23 | 1.23 | 1.31 | 1.15 | 1.40 | 1.35 |
| Profit before tax | 1.53 | 2.17 | 1.04 | 2.67 | 2.15 | 0.94 | 1.15 | 0.75 |
| Tax | 0.41 | (0.46) | 0.68 | 1.52 | 0.76 | (1.96) | 0.01 | 0.01 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.43 | 48.75 | 42.59 | 51.00 | 53.81 | 40.93 | 42.05 | 44.05 |
| Revenue growth (YoY) | -10.0% | +19.1% | +1.3% | +15.8% | +65.8% | - | - | - |
| Other income | 0.42 | 0.16 | 0.25 | 0.29 | 0.55 | 0.22 | 0.00 | 0.14 |
| Total expenses | 44.10 | 42.05 | 39.05 | 45.87 | 49.38 | 37.50 | 38.03 | 40.62 |
| EBITDA | 4.33 | 6.70 | 3.54 | 5.13 | 4.43 | 3.43 | 4.02 | 3.43 |
| EBITDA margin | +8.9% | +13.7% | +8.3% | +10.1% | +8.2% | +8.4% | +9.6% | +7.8% |
| Depreciation | 1.59 | 1.93 | 1.52 | 1.52 | 1.52 | 1.56 | 1.47 | 1.47 |
| Interest | 1.63 | 2.76 | 1.23 | 1.23 | 1.31 | 1.15 | 1.40 | 1.35 |
| Profit before tax | 1.53 | 2.17 | 1.04 | 2.67 | 2.15 | 0.94 | 1.15 | 0.75 |
| Tax | 0.41 | (0.46) | 0.68 | 1.52 | 0.76 | (1.96) | 0.01 | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 196 | 159 | 197 | 183 | 200 | 182 | 167 |
| Revenue growth | +23.0% | -19.1% | +7.8% | -8.5% | +10.2% | +8.6% | - |
| Other income | 1.25 | 0.68 | 0.89 | 6.94 | 2.21 | 1.06 | 1.45 |
| Total expenses | 176 | 152 | 186 | 182 | 194 | 159 | 148 |
| Employee cost | 15.48 | 16.35 | 18.80 | 16.30 | 16.33 | 15.26 | 13.30 |
| EBITDA | 19.81 | 7.25 | 10.99 | 0.93 | 6.43 | 22.84 | 19.16 |
| EBITDA margin | +10.1% | +4.6% | +5.6% | +0.5% | +3.2% | +12.6% | +11.5% |
| Depreciation | 6.48 | 5.96 | 5.80 | 4.47 | 3.80 | 3.37 | 3.21 |
| Interest | 6.53 | 5.19 | 5.47 | 3.31 | 3.10 | 3.26 | 3.32 |
| Profit before tax | 8.05 | (3.22) | 0.61 | 0.09 | 1.74 | 17.27 | 14.08 |
| Tax | 2.50 | (1.95) | 0.47 | 0.28 | 0.60 | 3.56 | 3.20 |
| Net profit | 5.55 | (1.27) | 0.14 | (0.09) | 1.14 | 13.71 | 10.88 |
| Net profit margin | +2.8% | -0.8% | +0.1% | -0.1% | +0.6% | +7.6% | +6.5% |
| EPS (₹) | 5.71 | (1.33) | 0.17 | (0.23) | 1.43 | 17.14 | 13.62 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.71 | 9.71 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
| Reserves & surplus | 65.77 | 59.24 | 37.84 | 38.21 | 38.80 | 38.58 | 26.20 |
| Shareholders' funds (net worth) | 75.48 | 69.95 | 45.84 | 46.21 | 46.80 | 46.58 | 34.20 |
| Secured loans | 45.73 | 45.75 | 55.27 | 50.85 | 38.36 | 22.57 | 17.94 |
| Unsecured loans | 4.20 | 2.12 | 2.52 | 0.20 | 0.42 | 0.33 | 0.00 |
| Total debt | 49.93 | 47.87 | 57.79 | 51.05 | 38.78 | 22.90 | 17.94 |
| Total liabilities | 128 | 120 | 105 | 99.52 | 89.34 | 71.52 | 56.57 |
| Assets | |||||||
| Gross block | 111 | 108 | 104 | 101 | 91.41 | 82.21 | 74.31 |
| Net block | 46.22 | 49.60 | 52.33 | 54.46 | 48.97 | 43.57 | 39.04 |
| Capital work in progress | 22.07 | 23.22 | 21.02 | 11.59 | 8.03 | 0.08 | 1.13 |
| Investments | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
| Inventories | 44.81 | 45.25 | 43.76 | 46.74 | 41.49 | 32.92 | 27.40 |
| Sundry debtors | 116 | 88.43 | 100 | 76.33 | 68.57 | 50.62 | 44.30 |
| Cash & bank balances | 0.65 | 6.64 | 0.83 | 0.83 | 0.65 | 1.66 | 2.00 |
| Loans & advances | 5.81 | 7.58 | 5.31 | 8.58 | 7.17 | 4.05 | 5.44 |
| Total current assets | 167 | 148 | 150 | 132 | 118 | 89.25 | 79.14 |
| Total current liabilities | 110 | 101 | 117 | 98.18 | 84.76 | 60.28 | 60.69 |
| Net working capital | 57.90 | 46.64 | 33.04 | 34.30 | 33.12 | 28.97 | 18.45 |
| Total assets | 128 | 120 | 105 | 99.52 | 89.34 | 71.52 | 56.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 6.09 | 0.27 | 0.27 | 0.65 | 1.66 | 2.00 | 1.96 |
| Net cash from operating activities | 4.17 | (5.38) | 16.42 | 18.42 | 13.74 | 13.53 | 9.71 |
| Net cash from investing activities | (1.72) | (5.17) | (13.32) | (15.59) | (16.82) | (11.82) | (6.31) |
| Net cash from financing activities | (8.45) | 16.36 | (3.10) | (2.65) | 2.07 | (2.05) | (3.36) |
| Net change in cash | (5.99) | 5.82 | 0.00 | 0.18 | (1.01) | (0.34) | 0.04 |
| Closing cash | 0.65 | 6.64 | 0.83 | 0.83 | 0.65 | 1.66 | 2.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +23.0% | -19.1% | +7.8% | -8.5% | +10.2% | +8.6% | - |
| EBITDA growth | +173.2% | -34.0% | +1081.7% | -85.5% | -71.9% | +19.2% | - |
| PBT growth | +9998.0% | - | +577.8% | -94.8% | -89.9% | +22.7% | +14.3% |
| Net income growth | +537.0% | -1007.1% | +255.6% | -107.9% | -91.7% | +26.0% | - |
| Revenue CAGR (3Y) | +2.3% | -7.3% | +2.8% | +3.1% | +8.7% | +17.4% | +16.1% |
| EBITDA CAGR (3Y) | +177.2% | +4.1% | -21.6% | -63.5% | -28.8% | +47.7% | +47.3% |
| Profitability & leverage | |||||||
| Net income margin | +2.8% | -0.8% | +0.1% | -0.1% | +0.6% | +7.6% | +6.5% |
| Return on capital employed | +11.8% | +1.7% | +5.9% | +3.6% | +6.0% | +32.1% | +32.5% |
| Return on net worth | +7.6% | -2.2% | +0.3% | -0.2% | +2.4% | +34.0% | +36.2% |
| Debt / equity | 0.67 | 0.91 | 1.18 | 0.97 | 0.66 | 0.51 | 0.65 |
| Long-term debt / equity | 0.11 | 0.21 | 0.29 | 0.24 | 0.18 | 0.13 | 0.15 |
| Interest cover | 48.99 | 402.33 | 105.39 | -93.50 | 117.87 | 16.74 | 20.82 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.06 | 1.72 | 2.20 | 2.17 | 2.65 | 2.65 | 2.57 |
| Inventory turnover | 5.01 | 4.10 | 5.01 | 4.73 | 6.19 | 6.88 | 8.27 |
| Debtors turnover | 2.20 | 1.93 | 2.57 | 2.88 | 3.86 | 4.37 | 4.46 |
| EPS (₹) | 5.71 | (1.33) | 0.17 | (0.23) | 1.43 | 17.14 | 13.62 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.50 | 1.00 |
| Book value per share (₹) | 77.73 | 71.00 | 57.30 | 57.77 | 58.50 | 58.22 | 42.75 |
To see the full year-wise statements and ratios of Everest Organics Limited, buy the company report.
Board of directors of Everest Organics Limited
Everest Organics has 7 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hari Krishna Srikakarlapudi | Whole-Time Director | 29 Sep 2007 | 19 Years 1 Months | Current |
| Srikakarlapudi Sirisha Also directs: Everest Life Sciences Private Limited | Managing Director | 30 Jul 2014 | 12 Years 3 Months | Current |
| Kirankumar Rampally Also directs: Photon Life Sciences LLP | Director | 13 Jan 2025 | 1 Years 9 Months | Current |
| Venkata Satyanarayana Murthy Vadali | Director | 13 Nov 2024 | 1 Years 11 Months | Current |
| Prasad Venkata Satya Sundara Srikakolapu | Director | 01 Sep 2023 | 3 Years 2 Months | Current |
| Venkata Satya Subbarao Pachigolla Also directs: Webrocket Tech Private Limited | Whole-Time Director | 12 Nov 2025 | 0 Years 11 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Everest Organics Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Everest Organics Limitedthis company | ₹196.16 Cr (FY 2026) | ₹5.55 Cr | 2.8% | 23.0% | 387 | Medak, Telangana, India |
| S.V. Labs Private Limited | ₹162.99 Cr (FY 2025) | 0.0% | Hyderabad, Telangana, India | |||
| Vasista Life Sciences Private Limited | ₹162.88 Cr (FY 2025) | 19.0% | Hyderabad, Telangana, India | |||
| Syntho Chirals Private Limited | ₹162.38 Cr (FY 2024) | 23.0% | Hyderabad, Telangana, India | |||
| Vivin Drugs & Pharmaceuticals Private Limited | ₹161.52 Cr (FY 2023) | -25.0% | Hyderabad, Telangana, India | |||
| Valentis Laboratories Private Limited | ₹160.96 Cr (FY 2025) | 135.0% | Sangareddy, Telangana, India | |||
| Infinium Pharmachem Limited | ₹157.83 Cr (FY 2025) | 15.0% | Sojitra, Gujarat, India | |||
| Gujarat Themis Biosyn Ltd | ₹153.23 Cr (FY 2025) | -12.0% | Valsad, Gujarat, India | |||
| Allchem Lifescience Limited | ₹152.78 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India | |||
| Rampex Labs Private Limited | ₹152.68 Cr (FY 2025) | 16.0% | Bollaram Villege, Telangana, India |
To see the full peer comparison of Everest Organics Limited, buy the company report.
Auditor
Everest Organics Limited is audited by P.S.N RAVISHANKER & ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| P.S.N RAVISHANKER & ASSOCIATES | FY 2024 | 003228S |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 59.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 40.40%.
Mar 2026
QUARTER
59.60% Promoters
40.40% Retail & Others
Promoter holding - history
Now 59.60% · Mar 2026High 61.00% · Jun 2025Low 59.60% · Sep 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 59.60% | 59.60% | 59.60% | 61.00% |
| Public | 40.40% | 40.40% | 40.40% | 39.00% |
Charges & borrowings
Open charges
₹73.38 Cr
Satisfied charges
₹118.08 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Mar 2023 | 100693601 | Canara Bank | ₹15 Cr | Open | |
| 18 May 2022 | 100583048 | Others | ₹16.75 Lakh | Open | |
| 31 Mar 2021 | 100454877 | Axis Bank Limited | ₹64.16 Lakh | Open | |
| 28 Dec 2020 | 100443191 | Hdfc Bank Limited | ₹57.34 Cr | Open | |
| 18 Mar 2020 | 100398218 | Axis Bank Limited | ₹23.7 Lakh | Open |
To see the full charge records of Everest Organics Limited, buy the company report.
Total charge records: 30 View all charges
Deals & funding
Everest Organics Limited has 7 deals on record (3 market trades, 3 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹38.39 Cr; the latest was in June 2025.
Total deals
7
Market trades
3
Funding rounds
3
Convertible or debt financing
1
Disclosed funding
₹38.39 Cr
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2025 | Market trade | ₹2.25 Cr | Seller: Bk Legacy Trust |
| Apr 2025 | Market trade | ₹1.33 Cr | Buyer: an individual |
| Jan 2025 | Funding round | ₹26 Cr | Investors: Greenpath Energy Private Limited , 3 individuals |
| Jan 2025 | Funding round | ₹4 Cr | Investors: an individual |
| Sep 2016 | Funding round | ₹7.11 Cr | Investors: Veerat Finance and Investment Limited , an individual |
To see the full deal history of Everest Organics Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Everest Organics Limited has 52 court cases on record: 36 filed by Everest Organics, 16 filed against it. 14 cases are pending and 38 are disposed.
Total cases
52
Filed by the company
36
Filed against the company
16
Pending
14
Disposed
38
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 25 | 6 | 4 |
| District courts | 17 | 9 | 6 |
| NCLAT | 6 | 0 | 4 |
| Supreme Court | 4 | 1 | 0 |
Cases on record (5 of 52)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Court case (COS) | Filed against the company by Ms RR Innovative Private Limited | Pending |
| District court, Sangareddy, Telangana | Execution petition | Filed against the company by Mysore Ammonia and Chemicals Limited Rep by Its Ar Vade Venkat Ramana Reddy | Pending |
| District court, Hyderabad Central, Telangana | Cheque dishonour complaint | Filed against the company by M/S. Tagoor Laboratories Pvt. Ltd., Rep. by Its Authorised Collection Executive Mr. G.Mohan Rao | Pending |
| NCLAT, Court I | Tribunal matter | Filed by the company against PSN Medicare Pvt. Ltd. and 2 others | Pending |
| NCLAT, NCLAT Chennai | Interim or miscellaneous application | Filed by the company against Leesa Lifesciences Pvt Ltd and 2 others | Pending |
To see the full case history of Everest Organics Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Everest Organics Limited was last rated by Icra on 08 Jun 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 08 Jun 2022 |
To see the full credit ratings and regulatory alerts of Everest Organics Limited, buy the company report.
MSME payment delays
Everest Organics Limited has 18 MSME Form 1 returns on record between 2019 and 2024, listing 3,449 overdue payments to 111 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 111)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sri Vasavi Chemical Corporation | |||
| an individual supplier | |||
| Virgin Acids & Solvents Private Limited | |||
| Pragati Polyplast India Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Everest Organics Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Everest Organics Limited has a workforce of 387 employees on its EPFO records as of Jan 26, 2025, across 1 active EPFO establishment.
Employee count
387
Active EPFO establishments
1
Employee growth
-2.03%
GST
Everest Organics has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAACE4400F1Z9 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Everest Organics Limited, buy the company report.
Recent activity
Everest Organics Limited has 29 board changes on record since 1993: 18 appointments and 11 cessations. The latest: Ramana Narra Venkata was appointed as Additional Director on 29 May 2026.
Appointed
Ramana Narra Venkata was appointed as Additional Director.
Filing
Everest Organics Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Appointed
Venkata Satya Subbarao Pachigolla was appointed as Whole-Time Director.
AGM
Everest Organics Limited last Annual general meeting of members was held on 27 Sep 2025 as per latest MCA records.
Appointed
Kirankumar Rampally was appointed as Director.
Ceased
Akella Parvathisem ceased to be Director.
Appointed
Venkata Satyanarayana Murthy Vadali was appointed as Director.
Ceased
Venkatasatyanarayana Murthy Chayaly ceased to be Director.
Ceased
Ramakrishnam Raju Kounparaju ceased to be Director.
Ceased
Raju Sitarama Kakarlapudi ceased to be Director.
Charges
A charge with Hdfc Bank Limited of Rs. 57.34 Cr registered on 28 Dec 2020 with Charge ID 100443191 was modified on 31 Jan 2024.
Appointed
Prasad Venkata Satya Sundara Srikakolapu was appointed as Director.
87 earlier events are in the company report.
News
Frequently asked questions
Everest Organics is an active public limited company based in Medak, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 19 February 1993 (33+ years old) and is registered under CIN L24230TG1993PLC015426. Listed on BSE: 524790.
Everest Organics reported revenue of ₹196.16 Cr for FY 2025-26 (up 23% YoY) based on standalone financials.
Everest Organics has 7 current directors:
- Srikakarlapudi Sirisha - Managing Director
- Hari Krishna Srikakarlapudi - Whole-Time Director
- Venkata Satya Subbarao Pachigolla - Whole-Time Director
- Kirankumar Rampally - Director
- Venkata Satyanarayana Murthy Vadali - Director
- Prasad Venkata Satya Sundara Srikakolapu - Director
- Ramana Narra Venkata - Additional Director
The latest financial statements of Everest Organics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Everest Organics is 36AAACE4400F1Z9, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Everest Organics is L24230TG1993PLC015426. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Everest Organics is a listed company as per MCA records. Its shares are listed on BSE (code: 524790).
Everest Organics has 52 court cases on record: 36 filed by the company and 16 filed against it. 14 are pending. Most are in the high courts.
Everest Organics was incorporated on 19 February 1993, making it 33+ years old. It is registered with the Registrar of Companies, Hyderabad.
Everest Organics has 7 deals on record (3 market trades, 3 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹38.39 Cr; the latest was in June 2025.
The peers of Everest Organics by revenue are S.V. Labs Private Limited, Vasista Life Sciences Private Limited, Syntho Chirals Private Limited, Vivin Drugs & Pharmaceuticals Private Limited, Valentis Laboratories Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ramana Narra Venkata was appointed as Additional Director on 29 May 2026. Venkata Satya Subbarao Pachigolla was appointed as Whole-Time Director on 12 Nov 2025. Kirankumar Rampally was appointed as Director on 13 Jan 2025. Everest Organics has 29 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages